Skip to main content

A quantitative ELISA-based co-culture angiogenesis and cell proliferation assay

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Friis T, Kjær Sørensen B, Engel AM, Rygaard J, Houen G. A quantitative ELISA-based co-culture angiogenesis and cell proliferation assay. APMIS 2003;111:658–68.

Since solid tumours and metastases depend on adequate blood supply, much research is focused on inhibition of angiogenesis. Unfortunately, most known angiogenesis inhibitors have serious side effects when used as therapeutic agents in man. It is therefore important to develop methods to identify well-tolerated and efficient angiogenesis inhibitors. As a method for identification of new angiogenesis inhibitors we have further developed the procedure described by Bishop et al. (Angiogenesis 1999;3:335–44) to a quantitative ELISA-based fibroblast and endothelial cell co-culture angiogenesis assay. In each well of a 96-microwell plate, human umbilical vein endothelial cells (HUVEC) are seeded onto normal human dermal fibroblasts (NHDF) and propagated in co-culture for 72 h with or without a potential angiogenesis inhibitor. The effect on total cell proliferation is evaluated by quantitative immunochemical measurement of DNA, and on endothelial tube formation by quantification of CD 31, von Willebrand factor, and collagen IV. After ELISA reading, the morphology of the tubular structures formed by HUVEC is visualised with BCIP/NBT, permitting a quantitative result and a qualitative evaluation of cell morphology from the same well. We have used the assay to demonstrate the effect of well-known angiogenesis inhibitors on HUVEC tube formation.

Keywords: Angiogenesis; CD 31; ELISA; co-culture; collagen IV; endothelial tube formation; von Willebrand factor

Document Type: Research Article

DOI: https://doi.org/10.1034/j.1600-0463.2003.1110609.x

Affiliations: 1: Department of Research and Development, Division of Plasma Products, Statens Serum Institut, Copenhagen, Denmark, and 2: Bartholin Instituttet, Division of Immunology and Cancer, Rigshospitalet, Copenhagen, Denmark

Publication date: 2003-06-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more